A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay
Matthew Chase(Brigham and Women's Hospital), Jennifer L. Crombie(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Philippe Armand(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Allison P. Jacob(Laboratoire d'Innovation Thérapeutique), Ann S. LaCasce(Otsuka (Japan)), Jennifer R. Brown(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k